PPA
TBPH icon

Parametric Portfolio Associates’s Theravance Biopharma TBPH Stock Holding History

Parametric Portfolio Associates’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$707K Sell
73,983
-623
-0.8% -$6.11K ﹤0.01% 2939
2021
Q4 		$824K Buy
74,606
+29,278
+65% +$255K ﹤0.01% 2863
2021
Q3 		$335K Buy
45,328
+24,028
+113% +$269K ﹤0.01% 3257
2021
Q2 		$309K Buy
21,300
+1,097
+5% +$20.6K ﹤0.01% 3264
2021
Q1 		$412K Sell
20,203
-1,554
-7% -$29.5K ﹤0.01% 3584
2020
Q4 		$387K Sell
21,757
-2,664
-11% -$47.8K ﹤0.01% 3493
2020
Q3 		$361K Sell
24,421
-60,855
-71% -$1.14M ﹤0.01% 3410
2020
Q2 		$1.79M Buy
85,276
+28,108
+49% +$722K ﹤0.01% 2565
2020
Q1 		$1.32M Buy
57,168
+25,692
+82% +$643K ﹤0.01% 2625
2019
Q4 		$815K Sell
31,476
-24,097
-43% -$468K ﹤0.01% 3159
2019
Q3 		$1.08M Buy
55,573
+37,022
+200% +$748K ﹤0.01% 2977
2019
Q2 		$303K Sell
18,551
-2,570
-12% -$52.1K ﹤0.01% 3578
2019
Q1 		$479K Buy
21,121
+1,139
+6% +$28.9K ﹤0.01% 3360
2018
Q4 		$511K Buy
19,982
+4,659
+30% +$126K ﹤0.01% 3299
2018
Q3 		$501K Buy
15,323
+2,184
+17% +$59.5K ﹤0.01% 3417
2018
Q2 		$298K Sell
13,139
-15,543
-54% -$369K ﹤0.01% 3558
2018
Q1 		$696K Buy
28,682
+9,248
+48% +$254K ﹤0.01% 3190
2017
Q4 		$542K Buy
19,434
+4,642
+31% +$137K ﹤0.01% 3286
2017
Q3 		$506K Buy
14,792
+549
+4% +$18K ﹤0.01% 3417
2017
Q2 		$567K Buy
14,243
+153
+1% +$5.88K ﹤0.01% 3292
2017
Q1 		$519K Buy
14,090
+456
+3% +$14.6K ﹤0.01% 3190
2016
Q4 		$435K Buy
13,634
+1,063
+8% +$33K ﹤0.01% 3263
2016
Q3 		$456K Sell
12,571
-1,531
-11% -$42.6K ﹤0.01% 3217
2016
Q2 		$320K Buy
14,102
+3,314
+31% +$71.6K ﹤0.01% 3426
2016
Q1 		$203K Sell
10,788
-524
-5% -$8.57K ﹤0.01% 3737
2015
Q4 		$185K Buy
+11,312
New +$180K ﹤0.01% 3751

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Parametric Portfolio Associates's TBPH Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its Theravance Biopharma (TBPH) stake by 0.84% in Q1 2022, selling an estimated $6.11K and leaving 73,983 shares worth $707K. The position accounts for ﹤0.01% of the portfolio, ranked #2939.

Parametric Portfolio Associates first reported a position in TBPH in Q4 2015 and has held it in 26 quarters since. The position peaked at $1.79M in Q2 2020. 121 funds tracked by Wall St. Rank hold TBPH as of Q1 2022.

  • Parametric Portfolio Associates held 73,983 shares of Theravance Biopharma worth $707K as of Q1 2022.
  • Parametric Portfolio Associates sold 623 Theravance Biopharma shares in Q1 2022, an estimated $6.11K.
  • Theravance Biopharma made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #2939 holding.
  • Parametric Portfolio Associates first reported a position in Theravance Biopharma in Q4 2015 and has held it in 26 quarters since.
  • Parametric Portfolio Associates's Theravance Biopharma position peaked at $1.79M in Q2 2020.
  • 121 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.